Oculis Holding AG (OCS) Debt Ratio (2021 - 2022)
Oculis Holding AG's (OCS) quarterly Debt Ratio came in at 3.3 in Q4 2022, up 68.96% year-on-year from 1.96 in Q4 2021, and up 68.96% quarter-over-quarter from 1.96 in Q4 2021.
Oculis Holding AG (OCS) Debt Ratio (2021 - 2022) Analysis & Trends
Oculis Holding AG's Debt Ratio history runs 2 years deep, the most recent figure standing at 3.3 for Q4 2022.
- On a quarterly basis, Debt Ratio rose 68.96% year-over-year to 3.3 in Q4 2022; TTM through Dec 2022 was 3.3, a 68.96% increase from a year earlier, with the FY2022 full-year figure at 3.3, up 68.96% from the prior year.
- Debt Ratio improved to 3.3 in Q4 2022 per OCS's latest filing, from 1.96 in the prior quarter.
- Across five years, Debt Ratio topped out at 3.3 in Q4 2022 and bottomed at 1.96 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 1.41 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.11 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 3.30 |
| Dec 31, 2021 | 1.96 |